Biomarker-Driven Treatments for Ovarian Cancer: Moving Beyond HRD?
Abstract Ovarian cancer is a biologically heterogeneous disease, yet for more than two decades its standard treatment of surgery and platinum–taxane chemotherapy changed little. Only a modest additional benefit was seen with the addition of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor...